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Abstract Tuberculosis (TB) is still the world’s second most
frequent cause of death due to infectious diseases after HIV
infection, and this has aroused greater interest in identifying
and managing exposed subjects, whether they are simply
infected or have developed one of the clinical variants of the
disease. Unfortunately, not even the latest laboratory tech-
niques are always successful in identifying affected children
because they are more likely to have negative cultures and
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tuberculin skin test results, equivocal chest X-ray findings,
and atypical clinical manifestations than adults. Furthermore,
they are at greater risk of progressing from infection to active
disease, particularly if they are very young. Consequently,
pediatricians have to use different diagnostic strategies that
specifically address the needs of children. This document de-
scribes the recommendations of a group of scientific societies
concerning the signs and symptoms suggesting pediatric TB,
and the diagnostic approach towards children with suspected
disease.
Introduction
Tuberculosis (TB) is still the world’s second most fre-
quent cause of death due to infectious diseases after
HIV infection [1], and this has aroused greater interest
in identifying and managing exposed subjects, whether
they are simply infected or have developed one of the
clinical variants of the disease. Unfortunately, not even
the latest laboratory techniques are always successful in
identifying affected children because they are more likely
to have negative cultures and tuberculin skin test (TST)
results, equivocal chest X-ray findings, and atypical clin-
ical manifestations than adults [2]. Furthermore, they are
at greater risk of progressing from infection to active
disease, particularly if they are very young [2].
Consequently, pediatricians have to use different diag-
nostic strategies that specifically address the needs of
children.
This document describes the recommendations of a group
of scientific societies concerning the signs and symptoms sug-
gesting pediatric TB, and the diagnostic approach towards
children with suspected disease.
Methodology
Using the Consensus Conference method on the basis of the
National Institutes of Health and the Italian National
Programme Guidelines [3, 4] (Table 1), relevant publications
in English were identified by means of a systematic review of
MEDLINE and the Cochrane Database of Systematic
Reviews from their inception until 31 December 2014. The
search strategy was Bchildren[Title/Abstract] OR
pediatric[Title/Abstract] OR paediatric[Title/Abstract] AND
tuberculosis[Title/Abstract] AND diagnosis[Title/Abstract]
OR signs[Title/Abstract] or symptoms[Title/Abstract] or
TST[Ti t le /Abst rac t ] or IGRA[Ti t le /Abst rac t ] or
microbioogy[Title/Abstract] or radiography[Title/Abstract]
AND English[lang])^.
The Working Group agreed on a list of clinical problems
related to diagnosing TB, and the evidence review procedures
concentrated on patients aged 0–18 years, and included
section-specific targeted searches as well as formal systematic
reviews of selected aspects. The clinical recommendations
made in the updated international guidelines were also
reviewed and critically compared. The literature was critically
appraised by trained personnel using the Scottish
Intercollegiate Guidelines Network methodological checklists
[5], and all of the data were entered in tables of evidence for
each subject. The bibliographical material and a preliminary
draft document were given to the panel members before the
published evidence was presented and discussed at various
meetings. The Delphi method was used to reach a consensus
when the evidence did not provide consistent and unambigu-
ous recommendations [5]. The final text was revised on the
basis of these discussions and submitted by e-mail to the par-
ticipants at the Consensus Conference for final approval.
The multidisciplinary panel of clinicians and experts in
evidence-based medicine were identified with the help of
the participating scientific societies, and included experts
in the fields of general pediatrics, pediatric infectious dis-
eases, neonatology, infectious diseases, pneumology, mi-
crobiology, radiology, pharmacology, public health and
methodology. The panel was coordinated by the Italian
Society of Pediatric Infectious Diseases (SITIP). No panel
member declared any conflict of interest concerning the
contents of the guideline topics. The panel met on three
occasions, but many of the consultations involved in de-
veloping the document took place interactively by e-mail
or telephone.
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When should pediatric TB be clinically suspected?
Pulmonary signs and symptoms
Most diagnoses of pediatric TB (about 65 %) are made on the
basis of symptoms rather than case tracking, regardless of
whether TB is endemic or not in the country in which they
are made [6, 7].
The lungs are the most frequent site of pediatric TB
throughout the world: a recent retrospective study of more
than 2,500 children in the United States found that pulmonary
forms accounted for about 70 % of cases [8], which is essen-
tially similar to the 75.5 % found in an Italian study of more
than 200 affected children [9].
Given the extreme variability of pulmonary involvement
during the course of TB, the initial symptoms may also vary
widely depending on age, the child’s general clinical condi-
tion, the presence of underlying diseases, and the natural his-
tory of the disease; furthermore, TB symptoms may mimic
some common acute respiratory diseases.
The most frequently reported symptoms in children with
TB are cough lasting >4 weeks; a poor response to first-line
treatment; dyspnea and asthenia; chest pain, particularly in
older children and adolescents; and hemoptysis. In some case
series, the presence of individual symptoms such as cough
lasting >4 weeks have been highly predictive of TB (odds
ratio [OR] 13.8, 95 % confidence interval [95 % CI] 2.3–
83.1) [10], but such signs are often associated with a range
of general symptoms such as persistent and often moderate
evening fever, night sweats, general malaise and asthenia, and
weight loss.
Combinations of multiple symptoms have proved to be
highly predictive of TB in a number of large cohorts de-
scribed in South Africa. One study of more than 1,000
children classified as being at low (aged >3 years and
not infected with HIV) and high risk of TB (age
<3 years or HIV-infected) tested the sensitivity, specificity
and positive predictive value (PPV) of various symptoms
and signs [11], and found that the combination of persis-
tent and unremitting cough for >2 weeks, weight loss in
the previous 3 months, and asthenia had a sensitivity of
82.3 %, a specificity of 90.2 %, and a PPV of 82.3 % in
low-risk children, and corresponding values of 51.8, 92.%
and 90.1 % in high-risk children. However, symptoms
were poorly predictive of TB in the HIV-infected patients.
It has been found that the combination of cough and weight
loss (OR 5.4; 95 % CI 1.7–16.9; p=0.001) or cough, weight
loss and anorexia (OR 5.3: 95 % CI 1.5–18.8; p=0.004) is
significantly predictive of TB in children aged <15 years;
however, the presence of weight loss was required to reach
statistical significance [12]. Similar findings have been report-
ed in patients aged ≥15 years, in whom the probability of TB
increased about 17-fold in the case of associated weight loss,
chest/pleural pain and night sweats [13].
The pulmonary manifestations of pediatric TB are sig-
nificantly different at different ages. Breastfeeding infants
and school-aged children have extremely variable forms
that may be clinically and radiographically similar to
common respiratory infections but, as children grow, the
pathognomic pulmonary characteristics of TB become
gradually more similar until, by the time of adolescence,
they are the same as those observed in adults [6]. In some
cohorts of adolescents (aged 10–14 years) with an
ascertained diagnosis of TB, the percentage of cavitary
forms exceeds 80 % [12].
The radiological pictures of pediatric pulmonary TB
are also extremely heterogeneous and age related.
Moderate and aspecific parenchymal involvement (lobar
or interstitial pneumonia) is common, but there may also
be more typical pictures, such as cavitations, pleural effu-
sion, calcifications or multi-lobar involvement (particular-
ly the lower lobes). The presence of cavitations (OR 7.7,
95 % CI: 1.0–57.7) and the involvement of the upper
segments of the inferior lobes (OR 12.6, 95 % CI 1.2–
134.8) were found to be significantly associated with a
high risk of TB in a small Taiwanese case series [10].
Table 1 Quality of evidence and
strength of recommendation Quality of evidence
I Evidence from more than one properly designed, randomized, controlled study
and/or systematic review of randomized studies
II Evidence from one properly designed, randomized, controlled study
III Evidence from cohort studies or their meta-analysis
IV Evidence from retrospective case-controlled studies or their meta-analysis
V Evidence from case series without control group
VI Evidence from opinions of respected authorities, based on clinical experience
Strength of recommendation
A The panel strongly supports a recommendation for use
B The panel moderately supports a recommendation for use
C The panel marginally supports a recommendation for use
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Signs and symptoms of extra-pulmonary TB (EPTB)
EPTB accounts for 20–25 % of all cases of TB [14], and is
usually more difficult to diagnose than pulmonary forms not
only because it is less frequent, but also because its clinical
manifestations are extremely variable. The greatest diagnostic
difficulties are due to its aspecific manifestations, which mim-
ic those of other inflammatory or neoplastic diseases. It is
therefore necessary to maintain a high degree of suspicion in
order to make an early diagnosis, especially in a country with
a low prevalence of TB such as Italy.
Furthermore, EPTB can involve relatively inaccessible
sites and is characterised by a reduced bacillary load [14],
and it is often necessary to consider epidemiological, clinical,
immunological and imaging factors in order to make a
diagnosis.
In addition to localised symptoms, EPTB may also be
reflected by systemic symptoms; weight loss and a lack of
appetite are characteristic of disseminated and gastrointestinal
TB, whereas fever and night sweats, which are common in
disseminated, cerebral and gastrointestinal forms, are less fre-
quent in the case of lymph node, bone and genito-urinary TB
[15–18].
Extra-pulmonary involvement may be associated with a
pulmonary localisation, which makes diagnosis easier. In the
case of clinical suspicion, after the initial investigations have
excluded other possible etiologies, it is recommended to start
anti-TB treatment as soon as possible, particularly in the case
of severe forms such as disseminated TB and tuberculous
meningitis and pericarditis.
About 50 % of the forms of EPTB involve peripheral
lymph nodes, of which the most frequently involved are the
laterocervical and supraclavicular lymph nodes.
Lymphadenitis usually manifests itself in the form of the grad-
ual, non-painful swelling of one or more peripheral lymph
nodes. The nodes are initially hard and clearly delimited and
the overlying is skin is normal but, subsequently, the skin
tends to become inflamed and the nodes come together to
form hard lumps that may undergo spontaneous fistulasation
and release caseous material. Systemic symptoms are not fre-
quent except in HIV-infected subjects. The presence of a pain-
less lymphadenopathy of >2 cm that persists for >4 weeks and
is unresponsive to the usual antibiotics should always raise a
suspicion of TB [19, 20].
About 1% of the cases of TB in small childrenmay have an
osteoarticular localisation, which represents about 10–15% of
the forms of EPTB [21]. This is more frequent in children than
adults because the epiphyseal region of bones is more
vascularised in the former. The spinal column is affected in
50 % of cases, whereas the hips, elbows and knees are less
frequently involved, and involvement of the extremities is
even less frequent. The spinal form usually affects the thoracic
and lumbar vertebrae, usually two contiguous vertebrae but
sometimes more and sometimes separately. Systemic symp-
toms are not frequent in the case of bone and joint TB. The
most frequent symptom is pain, which usually progresses
more gradually than in other bacterial forms [21], and may
be accompanied by swelling and slight deformity. Kyphosis
affecting the thoracic region is a late sign suggesting spinal TB
[22]. Even in the early phases, there may sometimes be a
paravertebral or psoas abscess, with consequent muscle spasm
and movement alterations; neurological complications (Pott’s
disease) usually appear later.
In terms of laboratory findings, TB may be suggested by a
discrepancy between white blood cell counts and the erythro-
cyte sedimentation rate (ESR) [21]. C-reactive protein (CRP)
levels are usually normal, but there may be signs of chronic
inflammation: anemia, hypoalbuminemia, thrombocytosis
[23–27]. Furthermore, TB should be included in the differen-
tial diagnosis of isolated articular lesions (mainly of the hips
and knees), particularly if they are not painful. Nevertheless,
synovial fluid aspiration remains diagnostically decisive [26].
Tuberculous meningo-encephalitis (TBM) is the most seri-
ous form of pediatric TB, and appears in about 4–5 % of cases
of TB [28]. Mortality may be as high as 10–15 %, and about
half of the survivors have permanent neurological sequelae.
The early symptoms are aspecific, and include anorexia, mal-
aise, headache, and behavioural alterations. Breastfeeding in-
fants may only manifest a lack of appetite, irritability, somno-
lence, behavioural alterations, and convulsions. The prodromic
phase may last even several weeks, after which more specific
signs such as fever, headache, vomiting and nuchal rigidity
appear, the evolution of which is slower than in the case of
bacterial meningitis. These signs are followed by focal neuro-
logical symptoms associated with altered consciousness, re-
gression of neurodevelopmental cornerstones, and convulsion.
Cranial nerve paralysis particularly involves the III and VI
cranial nerves. Other neurological signs may develop depend-
ing on the site affected by arteritis or infarction: cerebellar
signs, extra-pyramidal movements, hemiparesis.
A number of studies have defined the clinical characteris-
tics predictive of TBM [29–33]. In addition to the symptoms
mentioned above, these highlight the importance of their du-
ration (>5 days) and the characteristics of cerebrospinal fluid
(CSF): a clear appearance; leukocytes 5–750/mL, with a prev-
alence of lymphocytes; proteins 0.5–3 g/dL; and a CSF/blood
glucose ratio of <50 %. These characteristics make it possible
to differentiate TBM from other bacterial forms, but they are
not decisive in the case of HIV-positive subjects insofar as
they do not allow the differentiation of TBM and cryptococcal
meningitis.
Pediatric abdominal TB is not very frequent [34]. It may
involve any tract of the intestine and peritoneum, although the
most common site is the ileocecal tract and the other parts of
the colon and rectum are less frequently affected. The most
frequent symptom is pain, which has a sub-acute or chronic
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course in two-thirds of cases, and may mimic appendicitis or
intestinal obstruction in the remaining third [35]. It may some-
times manifest itself as a palpable tumour-like mass with mal-
absorption or, at rectal level, as fistulae, abscesses, or anal
fissuring and bleeding. A combination of fever and abdominal
distension in a subject with ascites should arouse the suspicion
of a tuberculous form. Diagnostic confirmation always re-
quires invasive procedures [36].
Genito-urinary TB is one of the most frequent forms of
adult EPTB, but it is rare in small children and not very fre-
quent in adolescents because it appears at least 5 years after a
first infection [37]. The symptoms are local rather than sys-
temic, e.g. dysuria, hematuria and pollakiuria are frequent,
and associated with pain in the side. The symptoms are so
vague or mis-recognised that they are often only diagnosed
at an advanced stage of renal damage. It is sometimes diag-
nosed after a routine urine test; the presence of hematuria and
sterile pyuria in acidic urine should always prompt a search for
urinary M. tuberculosis [38].
Pericarditis is a rare form of TB that is still sometimes fatal,
particularly in HIV-positive subjects [39]. The initial symp-
toms are mainly systemic and aspecific, whereas cardiopul-
monary symptoms (cough, dyspnea, orthopnea, lower limb
edema, a dull retrosternal pain often influenced by position
and inspiration) appear later. The progression of the disease
and effusion may be accompanied by friction rubs, a sign of
cardiac tamponade or constrictive pericarditis. However, in
addition to images of exudative pericarditis, diagnosis always
requires pericardiocentesis or even pericardiotomy, particular-
ly in countries with a low prevalence of TB [39].
Disseminated TB is caused by the hematogenous dissemi-
nation of tubercular bacilli due to inadequate host defences,
and is therefore more frequent in children aged less than 2–
3 years, whose cell-mediated immune responses are still im-
mature [40] and, in breastfeeding infants, it may develop in
10–20 % of cases of TB due to a recent primary infection. It
has various clinical manifestations. The signs and symptoms
at the time of onset are generally systemic and non-specific,
e.g. fever, weight loss, night sweats, anorexia, and the loss of
appetite. The other symptoms depend on the predominantly
involved site; cough and other respiratory symptoms are asso-
ciated with pulmonary TB with a characteristic miliary ap-
pearance, whereas headache and altered consciousness are
associated with meningeal involvement. Choroidal tubercles,
which are pathognomic of miliary TB, can be observed in
30 % of cases [40]. However, no systematic diagnostic ap-
proach model has yet been defined [41].
How should pediatric TB be diagnosed?
A detailed anamnesis aimed at investigating possible exposure
to M. tuberculosis as a result of contact with someone with
bacilliferous TB or coming from an endemic area, and factors
favouring the development of the disease such as poor socio-
economic conditions is fundamental for a diagnosis of TB
[42]. Particular attention should be given to the presence of
concomitant medical conditions favouring immunosuppres-
sion, such as malnutrition, HIV-1 infection, or treatment with
corticosteroids or immunosuppressants [42].
Clinical analysis also plays a fundamental role, and all of
the signs and symptoms suggesting active disease should be
carefully evaluated: chronic cough, weight loss, asthenia, pro-
fuse sweating, fever, chest pain, hemoptysis and respiratory
distress [43].
Tuberculin skin test (TST)
Since 1907, a TST has been the reference diagnostic means of
detecting M. tuberculosis infection [15, 44]. The test is based
on the delayed hypersensitivity reaction induced by the intra-
dermal inoculation of a standardised dose of purified protein
derivative (PPD) tuberculin: theWHO recommends the use of
five units of PPD-S or two units of PPD tuberculin RT23.
Tuberculin reactivity usually appears between two and
12 weeks after the initial infection (median 3–4 weeks).
PPD is intradermally injected in a lesion-free area of the
volar forearm (Table 2). T lymphocytes sensitised by a previ-
ous infection are recruited at the site of the inoculation, where
they release lymphokines that induce local vasodilation, ede-
ma, fibrin deposition and the recruitment of other inflamma-
tory cells, resulting in an infiltrate that reaches its maximum
size 48–72 h after the injection [44]. The diameter of the
swelling should therefore be measured (in millimetres) within
this period by trained medical personnel. The result of the test
should be interpreted individually in relation to the presence
of conditions predisposing to TB, and the timing and type of
disease exposure as shown in Table 3.
ATST has some limitations, for example, it is an operator-
dependent test that requires the patient to make at least two
visits to a healthcare centre, and may give rise to false positive
or false negative results [44–47]. The possibility of false pos-
itive results is due to the cross-reactivity of the PPD antigens
with those of non-tuberculous mycobacteria and even of BCG
vaccine, even though the reactions rarely exceed 15 mm in
diameter [48]. The guidelines of the American Academy of
Pediatrics recommend using the same interpretation of TST
for children regardless of whether or not they have previously
received BCG [44] because the post-vaccination intradermal
reaction to tuberculin can be influenced by many factors, such
as the child’s immune status or age at the time of vaccination,
the quality and type of the vaccine strain, and the time interval
between the vaccination and the TST. Nevertheless, the same
guidelines suggest considering any hardening of more than
15 mm as positive in previously vaccinated children. The
specificity of the test obviously depends on the criteria used
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to define a positive result and the prevalence of non-tubercular
mycobacterial infections in the population considered.
Another possible cause of a false positive result is the booster
effect of repeated tests [49].
False negative results are possible when making an initial
evaluation of patients with active TB, especially in the case of
disseminated, miliary or pleural TB [50]. The main causes
underlying such findings include malnutrition and congenital
or acquired immunodeficiency, such as HIV-1 co-infection
[51], but other reasons may include recent TB infection, an
age of <2 years, recent vaccinations with attenuated live viruses
(such as an anti-measles vaccination), or ongoing viral infec-
tions such as measles, chickenpox or influenza [52]. It has been
reported that approximately 10–40 % of immunocompetent
Table 2 Tuberculin skin test (TST) procedure
Recommendation Reason
Check medical prescription Reduces the risk of error
Check the availability of the test and, if necessary, order a new supply Reduces the risk of error and increases the appropriateness of clinical
practice
Check the type of tuberculin available and, if the supplier has changed,
carefully read the technical data sheet
Reduces the risk of error
Inform the patient Guarantees the right of informed consent
Guarantee privacy Guarantees patient well-being
Have the patient adopt a comfortable position Reduces patient discomfort
Wash hands Reduces the risk of cross-infection
Wear non-sterile gloves Reduces the risk of cross-infection
Check the expiry date and characteristics of the drug to be administered Reduces the risk of error
Attach the needle to the syringe (1.0 mL), and reconstitute the solution by
aspirating the required dose from the vial (0.1 mL of PPD tuberculin
solution or 2 mL of PPD RM 23 solution)
Guarantees procedure is executed correctly
Aspirate the drug in the needle into the syringe Guarantees procedure is executed correctly
Replace the needle used to perforate the natural rubber membrane of the
vial containing the drug
Reduces procedure-related discomfort and pain. Increases patient comfort
Eliminate any air bubbles inside the syringe, and fill the new needle Guarantees procedure is executed correctly
Distract patient with the aid of an assistant, parent or specialised entertainer
if appropriate
Increases patient comfort, and reduces the child’s sensations of pain and
anxiety
Identify an appropriate administration site on the volar forearm. Avoid the
area near the elbow and the wrist
Guarantees procedure is executed correctly. Administration near the wrist
or elbow may be associated with false negative results
Carefully disinfect the administration site using centrifugal movements for
at least 20–30 s, and wait until the skin dries
Reduces the risk of infection. Guarantees procedure is executed correctly
Stretch the skin between the thumb and middle finger of the non-dominant
hand
Stretching the nerve ends in the skin reduces pain
Using the other hand, insert a short length of needle angled upwards into
the skin, maintaining a slope of 10–15° with respect to the plane of the
skin and penetrating 2–5 mm below the epidermis. The needle should be
visible through the epidermis during the insertion (Drug Technical Data
Sheet: Statens Serum Institute, 2014)
Avoids the risk of subcutaneous or intramuscular administration
During the administration, it should be possible to note a swelling of the
epidermis or a whitened area of about 6–10 mm (a sign that the
procedure has been corrected executed); if this does not occur, repeat the
administration on the other arm, or at a distance of at least 4 cm on the
same arm
Guarantees the test is executed correctly. If the injection is mistakenly
administered subcutaneously or intramuscularly, the papule will not
develop and the TST must be repeated.
Administer the drug as indicated in the technical data sheet Assures correct administration
Do not massage or press the administration site, but lightly dab it Avoids discomfort
Do not recap the needle after use and arrange for its disposal in the
appropriate container
Avoids the risk of accidental puncture
Highlight the injection site using an atoxic dermographic pen Guarantees the correct localisation of the inoculation site during the test
reading 48–72 h afterwards
Tell the child and his/her parents not to wash or scratch the forearm Prevents reddening or other manifestations that may confound the test
results
Dispose of waste material in accordance with current procedures Prevents the risk of accidents and cross-infection
Wash hands Prevents the risk of cross-infection
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children with confirmed microbiologically active TB are ini-
tially TST negative [50], and so a negative TST result does not
necessarily exclude the possibility of TB infection and/or dis-
ease [52].
Immunological tests for the diagnosis of pediatric TB
Interferon-gamma (INF-γ) release assays (IGRAs) measure
the INF-γ released by lymphocytes in response to in vitro
stimulation with specific M. tuberculosis antigens. Two tests
are currently marketed, namely, T-SPOT.TB (Oxford
Immunotec, Oxford, UK) and QuantiFERON-TB GOLD
(QFT-G, Qiagen, Venlo, The Netherlands) [53].
T-SPOT.TB uses the enzyme-linked immunospot
(ELISPOT) method to quantify IFN-γ-producing lympho-
cytes; the result is considered positive if >7 spots are detected,
negative if there are <5, borderline if there are 5–7, and inde-
terminate if there is no response [54]. QFT-G uses the enzyme-
linked immunosorbent assay (ELISA) method, and the result
is considered positive if >0.35 UI/mL of IFN-γ is produced
after specific antigen stimulation, and indeterminate if there is
no response in the mitogen-containing control tube [54]. The
antigens used in these tests are synthetic peptides that simulate
the early secreted antigenic target 6-kDa (ESAT 6) and culture
filtrate protein 10-kDa (CFP-10) of M. tuberculosis.
As IGRAs are in vitro tests, they are not operator depen-
dent, do not require a second visit to a healthcare facility, and
can be repeated any number of times without causing a boost-
er effect. However, there is evidence indicating that a previous
TSTcan alter IGRA results when there is only a 3-day interval
between them [55–57].
The tests have to be carried out scrupulously in accordance
with the instructions of the manufacturer; unreliable results in
a considerable proportion of patients have been reported to be
related to technical problems during the execution of the test,
including the drawing of insufficient blood from children. The
findings of some studies support the hypothesis that the per-
formance of the available IGRAs can be improved by
prolonging incubation times [58] or modifying the currently
used cut-off values on the basis of epidemiological or clinical
risk [59]. However, the evidence is still insufficient to be able
to recommend changes in the way the tests are carried out or
the results are interpreted [60].
The sensitivity and specificity of in-house tests or of tests
that use antigens or cytokines other than those in the marketed
tests described in the literature are extremely variable, and
cannot be recommended for use in clinical practice.
One of the advantages of IGRAs is that previous BCG
vaccination has little or no effect on the results. The ESAT-6
and CFP-10 are coded at the level of region of difference 1
(RD1) of the genome ofM. tuberculosis and, as these antigens
are not expressed in the genome of Mycobacterium bovis
BCG contained in the vaccine or in the genomes of the ma-
jority of non-tuberculous mycobacteria, it is often possible to
distinguish subjects with TB infection from those who have
been recently vaccinated and those with non-tubercular my-
cobacterial infections [61]. However, as the same antigens are
also expressed by some non-tubercular mycobacteria, such as
Mycobacterium avium, Mycobacterium kansaii, and
Mycobacterium szuigai, false positive results are still possible.
The performance of IGRAs has been documented in many
studies. One study of 336 children carried out in Italy in 2009
by Bianchi et al. suggested that they are more specific than a
TST in children with suspected TB infection [62], and a
German study of 73 children with latero-cervical
lymphoadenopathy comparing the TST with two IGRA
methods found that the specificity of QFT-G In-Tube (IT)
and T-SPOT was respectively 100 % (95 % CI 91–100 %)
Table 3 Definition of positive
tuberculin skin test (TST) results
in infants, children, and
adolescents
Diameter ≥5 mm • Children in close contact with people with known or suspected TB infection
• Children with chest radiography findings compatible with active TB
• Children with clinical signs of active TB
• Children receiving immunosuppressive treatment or with immunodepressive
conditions (e.g. HIV infection)
• Children aged <4 years
Diameter ≥10 mm • Children coming from or who have stayed in a country with a high prevalence
of TB disease
• Children living in poor socio-economic conditions
• Children with medical risk factors such as lymphoma, diabetes mellitus,
chronic renal insufficiency, malnutrition
• Children frequently exposed to adults with HIV infection, the homeless, drug
addicts, people living at healthcare residences, prisoners, institutionalised
subjects, migrant farm workers
Diameter ≥15 mm • Children aged >4 years without risk factors for TB infection
Modified from American Academy of Pediatrics [44]
TB tuberculosis
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and 98 % (95 % CI 87–100 %), whereas that of the TST was
only 58 % (95 % CI 42–73 %) [63].
A number of systematic reviews have revealed differences
in sensitivity and specificity in different populations [64].
However, these meta-analyses need to be interpreted critically
because the studies involved often used different diagnostic
criteria to define active TB, only a few were based on head-to-
head comparisons of T-SPOT.TB and QTF-G-IT, and various
cut-off values were used to define TST positivity.
It is also necessary to remember that the TST and IGRAs
cannot differentiate active TB and latent infection, and that
their performance in children aged <5 years and
immunodepressed subjects seems to be sub-optimal. The re-
ported sensitivity of T-SPOT.TB and QFT-G- IT in children,
respectively, range from 62 to 89 % and from 66 to 83 %. In
2010, Bamford et al. [65] studied 333 children in the United
Kingdom and found that the sensitivity of the TST, QFT-G IT
and T-SPOT.TB was 82, 78 and 66 %, respectively, whereas
the combined use of TST and QFT-G IT had a sensitivity of
96%, and that of TSTand T-SPOT.TBwas 91%. It is possible
that the TST is more sensitive because it is capable of explor-
ing multiple TH1- and TH2-mediated immunological mecha-
nisms, whereas IGRAs exclusively explore TH1-mediated re-
sponses, which may be immature in children in a manner that
is inversely proportional to their chronological age [64].
Furthermore, antigen-presenting cells in children are less ca-
pable of synthesising IL-12, a fundamental mediator in the
initial phase of TH1 polarisation [64].
Pediatric studies have also highlighted a larger proportion
of indeterminate results in children than in adults [64]. A re-
cent systematic review found that this proportion was 6.5 % in
the case of QFT-G IT and 3.5 % in the case of T-SPOT.TB
[66], but studies involving children aged <5 years have shown
that it may range from 0 to 40 % [67]. Some authors have
reported a larger proportion of indeterminate results not only
in children aged <5 years [68], but also in the case of helminth
co-infection, HIV-related immunosuppression, and immuno-
suppressive treatment [66]. A recent study has found that con-
comitant bacterial pneumonia may also be a risk factor in an
indeterminate result, particularly in children aged <5 years
[68]. In these situations, the increased risk may be due to
possibly age-related immune system immaturity leading to a
reduction in stimulated INF-γ production or an imbalance in
TH1/TH2-mediated responses.
The guidelines of the American Academy of Pediatrics
underline the fact that IGRA-positive children should be con-
sidered infected, and a negative or indeterminate result does
not exclude infection [44]. Furthermore, IGRAs are not rec-
ommended in children aged <5 years because of the lack of
unequivocal data or in immunocompromised children. The
2011 revision of the British NICE guidelines suggest a two-
step approach: a TST followed by the IGRA confirmation of
the TST-positive cases [69]. However, they also indicate
situations in which it is advisable to use an IGRA alone, such
as in the case of subjects who for any reason cannot be reached
a second time 48–72 h after a TST, or if it is necessary to
screen large numbers of children (including subjects aged
≥5 years), or when selected cases previously vaccinated with
BCG need to be investigated as a result of coming into contact
with subjects with contagious TB [69].
With reference to children aged <5 years, Detjen et al. eval-
uated the diagnostic accuracy of TST, T-SPOT.TB and QFT-
G-IT in 73 children with a mean age of 39 months—28 with
bateriologically confirmed TB, 23 with lymphadenitis due to
non-tubercular nycobacteria, and 22 controls [63]. The speci-
ficity of QFT-G-IT for TB was 100 % (95 % CI 91–100 %)
and that of T-SPOT.TB was 98% (95 % CI 87–100 %, but the
specificity of the TST was much less (58 %, 95 % CI 42–
73 %); the sensitivity of both IGRAs was 0.93 (95 % CI
0.77–0.99) and that of the TST was 1.00 (95 % CI 0.88–
1.00; k=0.91). In another study Okada et al. compared QFT-
G-IT and TST results in 195 Cambodian children living with
people with active TB, and found that the TST was more
specific in those who had previously undergone BCG vacci-
nation (k=0.63) [70]. Debord et al. retrospectively assessed
the performance of QFT-G-IT in 19 immunocompetent
French children with active TB aged <5 years (mean age
1.52 years) [71]. There were no indeterminate results and the
number of positive cases was 6/10 children aged <2 years and
9/9 children aged 2–5 years, thus suggesting that QFT-G-IT
may be a useful means of improving the diagnosis of TB in
association with TST in children aged <5 years [71]. The
studies of 397 South African children aged <3 years showed
good concordance between QFT-G-IT and TST results (k=
0.79); however, the sensitivity of both tests in detecting active
TB disease seemed to be poor (respectively, 38 and 35%) [72,
73]. On the contrary, Pavic et al. reported considerable discor-
dance between QFT-G-IT and TST results in 142 Croatian
children aged <5 years (k=0.59), and concluded that both
could be used in high-risk children aged <5 years provided
that positivity to either was considered a sign of infection [74].
The findings of a large-scale study of more than 1,000
adults suggest that IGRA (particularly T.SPOT.TB) can be
used to screen immunodeficient contacts of patients with TB
[75], but there are extremely few pediatric data. Bruzzese et al.
studied 80 HIV-negative immune-compromised children in
follow-up for liver transplantation or rheumatologic diseases
on biological treatment after coming into contact with TB
using both QFT-IT and T-SPOT; QFT-IT was positive in one
case (1.2%), whereas a significantly larger proportion of cases
(9.4 %) were positive to T-SPOT.TB (p=0.02) [76]. The au-
thors concluded that the high proportion of discordant or in-
determinate results meant that IGRAs were of little help in
diagnosing TB infection or disease in immunocompromised
children living in a country with a low prevalence of TB. The
other available studies suggest that IGRA may play a role in
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diagnosing TB infection and disease in the immunodepressed
[77–81], but their sample sizes were small.
IGRAs have little positive predictive value in indicating the
progression of active TB. Studies of adults and children have
clearly shown that the serial repetition of the tests during anti-
TB treatment does not aid the monitoring of therapeutic re-
sponses [82, 83].
What type of microbiological diagnosis should
be used for children with suspected TB?
The microbiological diagnosis of pediatric pulmonary TB is
still largely unsatisfactory, and its limited sensitivity is even
more marked in the case of immunocompromised subjects.
There are two main reasons for this: (1) the disease is typically
paucibacillary in children and (2) children are generally inca-
pable of providing sputum samples of acceptable quality [84].
It is therefore necessary to use alternative sampling methods,
all of which are sub-optimal [85].
Gastric aspiration is the most widely used method of
collecting swallowed respiratory secretions from children. It
is normally recommended that these samples should be
neutralised with sodium bicarbonate, but it has been recently
reported that this can significantly reduce culture yields in
liquid medium [86].
An alternative method is to induce sputum using a hyper-
tonic aerosol solution. This technique is not invasive but it
does require patient collaboration, which is not easy to obtain,
especially in the case of small children. A number of studies
have compared the diagnostic yield of gastric lavage and in-
duced sputum, sometimes including a comparison with naso-
pharyngeal aspirates. The results are not always concordant,
but the majority of studies have found that gastric lavage is the
most appropriate [87–94].
Broncholavage has the advantage of being aimed at the
lesioned site, but is rather invasive [95].
Another possibility is the string test. The patient swallows a
gelatin capsule containing a length of thread. The capsule
dissolves in the stomach, thus allowing the thread to become
impregnated with gastric secretions. Four hours later, the
thread is recovered and washed with 1–2 mL of saline solu-
tion, which is then used for the search [96].
A still inadequately evaluated approach is to search stool
for possible swallowed mycobacteria [97, 98].
It goes without saying that sputum is the sample of election
in the case of adolescents and children capable of producing it,
whereas gastric aspirate is the sample of election from the
youngest patients [94].
All of the samples should be collected in disposable, sterile
containers with screw caps [94] and, if they cannot be sent to
the laboratory immediately, should be stored in a refrigerator.
In order to increase sensitivity, microbiological investigations
for pulmonary TB are usually carried out on three samples
collected on consecutive days [99]; a single sample can be
used only in the case of broncholavage.
The sensitivity of a microbiological diagnosis of both adult
and pediatric TBM is limited by the availability of a sufficient
amount of CSF in which to seek Koch’s bacillus [94].
Diagnosing lymph node TB is less of a problem when a
bioptic sample is available [94].
A biopsy is also the sample of election in the case of pleural
TB; alternatively, searching an induced sputum sample is
much more useful than searching a pleural fluid sample [100].
Pediatric TB is quite rare in other body districts, and its
diagnosis raises similar problems to those associated with di-
agnosing their adult counterparts [94].
Table 4 shows the specifications of the various types of
biological samples, which may be examined microscopically,
cultured, or tested by means of gene amplification.
Although not very sensitive, a positive microscopic exam-
ination of a sample previously stained in such a way as to
reveal acid-fast bacilli allows prompt confirmation of a myco-
bacterial etiology [101]. The two most widely used stains are
Ziehl Neelsen and the more sensitive fluorescence staining,
but neither are capable of determining whether the mycobac-
terial infection is tubercular or not.
A culture examination is the gold standard of
mycobacteriological diagnostics, but it is less sensitive when
using respiratory samples taken from children than those taken
from adults [102]. With few exceptions (particularly CSF),
most biological samples are contaminated and therefore have
to be treated in order to eliminate the accompanying and rap-
idly multiplying bacterial flora that would otherwise irreme-
diably prevent the growth of possible mycobacteria. A myco-
bacterial culture requires the inoculation of a solid (generally
Löwenstein-Jensen) and liquid medium (the most widely used
is mycobacterial growth indicator tube [MGIT]), and
prolonged incubation at a temperature of 35–37 °C for up to
six (liquid media) or 8 weeks (solid media) before it can be
considered negative.
In the case of a positive culture, it is essential to identify the
species, or at least differentiate non-tubercular mycobacteria
from those belonging to theM. tuberculosis complex, because
both can grow in the most frequently used media. The isola-
tion ofM. tuberculosis complex is diagnostic for TB, but it is
often difficult to interpret the significance of finding a non-
tubercular mycobacterium [103].
Although gene amplification is less sensitive than a culture,
positive findings greatly reduce the time of diagnosis [104].
Laboratories equipped for mycobacterial diagnostics general-
ly also use amplification tests specific for the M. tuberculosis
complex whose sensitivity in the presence of a positive mi-
croscopic examination is practically 100 %, thus allowing a
rapid diagnosis; however, in the case of microscopically neg-
ative samples, their sensitivity is much less and also varies
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depending on the type of sample. If a sample is gene amplifi-
cation positive but microscopically negative, the albeit rare
possibility of contamination can be confirmed or ruled out
by repeating the test, preferably on a new sample [104]. It is
recommended to use gene amplification systems that include
the monitoring of inhibitors because, in the absence of these, a
negative result has no value. Despite its limitations, it is now
generally accepted that an amplification test combined with
microscopy and culture increases the sensitivity of a microbi-
ological diagnosis of TB. In the case of a grounded clinical
suspicion [105], the addition of gene amplification to conven-
tional tests provides an added value that should not be
underestimated in the largely deficient field of diagnosing
pediatric TB.
The commercial GeneXpert amplification test not only
reveals TB bacillus DNA, but also the presence of mu-
tations responsible for resistance to rifampicin [106,
107]. This can be useful when there is a strong suspicion
of infection due to multidrug-resistant (MDR) strains, i.e.
in the case of patients coming from countries with a high
incidence of MDR-TB who have come into contact with
people with MDR-TB or who have been previously treat-
ed with anti-TB drugs. Alternatively, a line probe assay
(LPA) can be used to test genotype resistance to the two
principal first-line drugs, namely, rifampicin and isonia-
zid [107].
Many of the commercial M. tuberculosis complex gene
amplification systems have only been validated for use on
respiratory samples, but there are nowmany published studies
showing that they are also useful for diagnosing EP-TB
[108–110].
In patients with a microbiological diagnosis of TB under-
going anti-TB treatment, responses can be periodically
monitored by means of microscopy and cultures alone, while
gene amplification is of no use [104].
Many published studies have clinically validated the
various commercial M. tuberculosis gene amplification
systems, some studies of which have included pediatric
samples. There are only small differences in performance
between them, and the only factor that has a significant
impact on their sensitivity is the volume of the processed
clinical sample [111]. The GeneXpert system, which has
been satisfactorily validated in a particularly large number
of recent studies, is characterised by the fact that it re-
quires very little effort on the part of the operator and
has a high inoculation capacity; it is possible to load up
to 0.5 mL of sample concentrated by means of centrifu-
gation [112, 113].
The first strain isolated from every patient should un-
dergo a phenotypic assay of drug susceptibility, particu-
larly its sensitivity to isoniazid, rifampicin, ethambutol
and pyrazinamide [114]. In the case of MDR strains re-
sistant to at least rifampicin and isoniazid, the assay
should be extended to second-line drugs and carried out
at a reference centre. Phenotypic assays are currently con-
sidered the gold standard for studying drug resistance, but
there are now also gentotypic tests available based on the
use of probes for detecting the mutations responsible for
resistance to rifampicin, isoniazid, ethambutol, quinolones
and aminoglycosides [115–117], which guarantee a rapid
response especially when they can be used directly on a
clinical sample. However, their sensitivity in detecting
resistance varies from 50 to 90 % depending on the drug,
and so the results must always be confirmed by a pheno-
typic test. Their use is recommended whenever infection
due to an MDR strain is suspected.
Table 4 Specifications for collecting biological samples for diagnosing tuberculosis (TB)
Material Requirements Instructions Unsuitable samples
Gastric aspirate At least 5 mL collected in the morning after
at least an 8-h fast on 3 consecutive days
Neutralisation with 100 mg of
sodium bicarbonate
Sputum At least 5 mL of deep sputum collected in
the morning on 3 consecutive days
Rinse the oral cavity with water
before collecting the sample
Saliva, pooled samples
Induced sputum At least 5 mL collected in the morning on
3 consecutive days
Delivery of hypertonic saline by
nebulizer
Broncholavage At least 3 mL Disinfection and sterilization of the
bronchoscope
Cavitary fluids 10–15 mL in a test tube with trisodium citrate
Cerebrospinal fluid At least 2 mL
Bioptic samples At least 1 g of tissue Samples in formalin (although a
molecular search is possible)
Pus The maximum possible amount collected
by means of a syringe and transferred into
a sterile test tube
Swabs with transport medium
Urine At least 40 mL of the first morning urine 24-h urine
Feces At least 1 g Not useful for a diagnosis of intestinal TB
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What radiological methods should be used in the case
of suspected pediatric TB?
Radiology for pulmonary TB
Pulmonary TB is associated with a variable spectrum of le-
sions which, if described as distinct pathologic entities, would
include pulmonary consolidations; lymph node disease, with
or without airway obstruction; a miliary pattern; cavitary le-
sions; and pleural effusion [118].
The radiological examination is based on antero-posterior
and lateral chest X-rays. The lateral projection improves visu-
a l i s a t i on o f po s t e r i o r l ymphadenomega l y and
lymphadenomegalies inferior to the intermediate bronchus
[118]. Furthermore, the usefulness of the lateral projection
and low radiation dose required lead to an advantageous
cost/benefit ratio [119].
Although the indications have not been standardised, the
investigation can be completed using computed tomography
(CT) with contrast medium. CT is clinically useful above all in
the case of children aged <5 years, particularly those aged
<2 years in whom conventional chest radiography is often
insufficient [118] because of the physiological protrusion of
the thymus. CT is also better than conventional radiology in
detecting calcifications, which are rare in the first years of life,
and the contrast medium makes it possible to assess intratho-
racic lymphadenomegalies [120], which are generally hilar
and mediastinic, and usually prevalent on one side. Normal
lymph node size in childhood is up to 7 mm (short axis).
Although aspecific, another suggestive pattern is that of the
Brim sign^ (low density in the centre of the lymph node
surrounded by a peripheral ring enhancement). Differential
diagnosis includes lymphoma, other infections such as HIV
infection or minor acute or chronic inflammation, and sarcoid-
osis (extremely rare).
In brief, even in the absence of clinical symptoms, the main
signs of active TB are consolidation and non-calcified hilar
lymphadenomegaly [121].
CT with contrast medium is the technique of choice for
defining lymphobronchial disease, a complication of pediatric
TB due to bronchial compression by an infected lymph node,
erosion, ulceration, infiltration, the intrabronchial flow of case-
ous material, and the formation of granulated tissue [122], thus
leading to air trapping, atelectasis, consolidation, necrosis and
cavitation. It is also better for evaluating tuberculous consoli-
dation and cavitation, identifying granulomas/tuberculomas,
and investigating complications (lymphobronchial disease,
pericarditis, outcomes). The use of CT for follow-up purposes
is strictly related to the clinical/radiological evolution of TB
[122]. Chest ultrasonography can play a role in evaluating
pleural and pericardial effusion [118], but there are no pediatric
data concerning the role of positron emission tomography
(PET).
The anatomo-radiological classification of Marais et al.
makes it possible to distinguish parenchymal and lymph node
disease and their evolutionary stages [123]. A parenchymal
Ghon focus may not be self-limiting, but cavitate and lead to
intrabronchial spreading and subsequent consolidation; this
expression is typical in adults but, although rare, is also pos-
sible in early infancy. However, what is typical in early infan-
cy is lymph node (lymphobronchial) disease with a progres-
sive cascade of the complications described above, which can
be best identified with CT. The disease may spread into the
pleural space, the pericardium or hematogenously (miliary
TB), with possible outcomes being calcification, parenchymal
destruction with fibrosis, and bronchiectasis. Andronikou
et al. have in fact integrated the classification of Marais et al.
with the findings of tomographic techniques [118].
Radiology for EPTB
Children with suspected EPTB should always undergo stan-
dard chest radiography [124], which is positive in 40–87 % of
the patients with the disease [125].
Cervical, submandibular, supraclavicular and pre-auricular
sites are the most typical locations of peripheral tuberculous
lymphadenitis. Imaging only plays a relatively important role
[126]; the examination of choice is ultrasonography, but the
only ultrasonographic sign suggesting tuberculous lymphade-
nitis is calcification, which usually appears late.
Osteo-articular TB often presents with symptoms that are
difficult to interpret, and so imaging represents a first ap-
proach [126]. Standard radiography reveals juxta-articular os-
teoporosis, peripheral bone erosion, gradual joint space
narrowing and, sometimes, a ‘cystic’ pattern with sclerotic
fissuring. Tuberculous dactylitis deserves particular mention;
it is characterised by the painless involvement of the short
tubular bones of the hands and feet, and radiographically re-
vealed fusiform tumefaction of the soft tissues with or without
periostitis. Subsequent alterations are a coarse trabecular pat-
tern with acro-osteolysis, reactive sclerosis, and joint involve-
ment [126].
Magnetic resonance imaging (MRI) is the technique of
choice for obtaining a complete osteo-articular anatomical
picture of all body regions, including an evaluation of possible
synovitis, soft tissue involvement, and cartilage destruction
[126].
Tuberculous spondylitis accounts for 30–50 % of cases of
tuberculous osteomyelitis [127], with the frequently affected
site in childhood being the dorso-lumbar junction. Standard
radiography may show disc space narrowing and various de-
grees of bone destruction, with possible kyphosis. Diagnosis
may be elusive or difficult, particularly in the lumbo-sacral
region. CT provides a complete picture of all bone segments
and is also capable of identifying collections of pus, but MRI
is the investigation of choice for a sinal evaluation (vertebral
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bodies, discs, the spinal canal, and paraspinal tissues). Bone
scintigraphy provides a whole-body evaluation of skeletal in-
volvement (an alternative is whole-body MRI mainly based
on STIR sequences).
The follow-up is based on radiography, with MRI being
used more frequently in cases of spinal locations, which re-
quire a careful evaluation not only of the bone [126, 127]. The
use of CT is largely limited to conditions that contraindicate
the use of MRI [126, 127].
In the case of central nervous system (CNS) TB, the typical
alterations are granulomatous lesions in the leptomeninges, to
the junction between the grey and white matter of the brain,
and in spinal cord [126]. The presence of tuberculomas can be
characteristic, whereas another manifestation is arteritis,
which may be responsible for severe ischemic events [126].
In the absence of other known manifestations, the diagnosis
of CNS TB can be difficult because the different neuroradiolog-
ical pictures simulate other pathological conditions, particularly
neoplasias. However, a combination of meningeal and paren-
chymal lesions should always arouse a suspicion of TB [128].
In an early phase, a cerebral CT scan without contrast me-
dium may be negative (10–15 % of cases), or show the pres-
ence of an iso-hyperdense exudate in the CSF-filled subarach-
noid spaces (basal cisterns and sulci) or iso-hyperdense,
roundish or oval masses (tuberculomas) that rarely contain
calcifications and are delimited by more or less extensive ede-
ma [128]. The administration of contrast medium leads to
intense enhancement of the basal cisterns, and marginal or
diffuse impregnation of the tuberculomas.
MRI provides much more information about CNS TB than
CT, the use of which is currently limited to emergency situa-
tions or the monitoring of hydroencephalus secondary to tu-
berculous meningo-encephalitis [129]. An MRI protocol for
studying suspected CNS TB should always include T1-
weighted (with and without contrast medium), turbo spin-
echo (TSE) and T2-weighted FLAIR images, diffusion-
weighted (DW) images, and possibly angio-MR arterial im-
ages (MRA). DW images are very useful for better
characterising tuberculoma signals and evaluating complica-
tions (ischemia, cerebritis) [129]. T1-weighted images with
contrast medium can reveal meningeal involvement as intense
enhancement and nodularity (an aspecific but very important
sign that is highlighted better by MRI than CT); vasculitis of
perforating vessels, which appears as puntate/linear enhance-
ment at the level of the basal ganglia; ventriculitis; plexitis
(rare); and pachymengitis (infrequent). Pienaar et al. found
that MRI showed basal meningeal enhancement in 97 % of
their patients with tuberculous meningo-encephalitis (as
against 70% in the case of CT), infarctions in 83% (as against
70 %), and granulomas in 40 % (as against 16 %) [129].
Angio-RMI can reveal vascular involvement such as alter-
ations in arterial profiles (stenoses, irregularities) or signs of
occlusion [129].
In the case of CNS TB, MRI with contrast medium should
also be extended to the whole spinal column in order to ex-
clude spinal meningitis, which is characterised by irregular
intradural enhancement, often with the formation of
perimedullary pseudo-cysts, medullary granulomas, and
misinterpreted vertebral alterations more or less associated
with CNS lesions [126].
Although challenging, imaging is also used to diag-
nose abdominal TB [128–131]. Standard radiography
can reveal signs of occlusion but ultrasonography and/
or CT are necessary as they can reveal porta hepatis, in
para-aortic sites, and mesenteric lymphadenomegalies
(the last being common in children). The presence of
calcifications and/or rim signs can suggest TB, whereas
the signs of peritonitis (thickening, stranding) are
aspecific. Gastrointestinal involvement manifests itself
as thickening and parietal contrast enhancement (particu-
larly at ileo-cecal level).
Micro- (0.5–2.0 mm) and macronodular hepatosplenic le-
sions are typical of disseminated disease [129–131]. The le-
sions are hypoechogenic/hypodense, and can suggest TB
when/if they calcify.
Renal TB is characterised by hydrocalycosis (papillary ne-
crosis) and lobar calcifications [129–131].
Conclusions
After analysing the published evidence and on the basis of
their own clinical experience, the group of experts reached
the following conclusions:
& Pediatric pulmonary TB should be suspected in the pres-
ence of the following symptoms and signs of pulmonary
involvement:
– Persistent, unremitting cough; cough lasting >4 weeks;
persistent chest pain; or hemoptysis [III-A].
– Cough or other respiratory signs and symptoms associat-
ed with long-lasting weight loss, asthenia/malaise and an
evening temperature of ≥37.5 °C [III-A].
– Forms of pneumonia poorly responding to first-line anti-
biotics or remitting/relapsing in nature, especially in sub-
jects at risk [V-B].
– Radiological pictures of pneumonia with signs typ-
ical of TB: calcifications, voluminous hilar and
mediastinic lymphadenomegalies prevalently on one
side, with or without airway obstruction (<5 years),
a miliary pattern, pulmonary consolidations/
cavitations (typical sites: the apical and posterior
segments of the upper lobe, and the apical segment
of the lower lobe), pleural effusion [III-A].
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& Tuberculous lymphadenopathy should be suspected in the
presence of:
– Persistent cervical lymphadenopathy (>4 weeks) with a
diameter of >2 cm, in the absence of a response to anti-
biotics or other local cause [III-B].
& Vertebral TB should be suspected in the presence of:
– Progressively increasing spinal pain; a discrepancy be-
tween leukocyte counts and the ESR; laboratory signs
of chronic inflammation (anemia, thrombocytosis, hypo-
albuminemia) [IV-B].
& Tuberculous meningitis (TBM) should be suspected in the
presence of:
– Headache, vomiting, irritability, lethargy, convulsions,
coma, nuchal rigidity, paralysis of the cranial nerves (par-
ticular III and VI) lasting >5 days. CSF with leukocytes
<1.000×103/mL, of which >50 % lymphocytes; protein
>100 mg/dL; CSF/plasma glucose ratio <50 %. CT/MRI
findings of basal meningeal enhancement, hydrocepha-
lus, cerebral infarction [IV-A].
& The differential diagnosis of less frequent cerebral
tuberculomas and other space-occupying forms is based
more on imaging than clinical criteria (convulsions, vary-
ing focal neurological signs depending on site,
endocranial hypertension) [V-B].
& Abdominal TB should be suspected in the presence of
distension and chronic abdominal pain, ascites, and is of-
ten associated with general symptoms such as fever and
weight loss [V-B].
& Genito-urinary TB should be suspected in the presence of
symptoms of recurrent urinary pathway infections or he-
maturia associated with sterile pyuria [V-B].
& In addition to images of exudative pericarditis, the diag-
nosis of tuberculous pericarditis always requires
pericardiocentesis or pericardiotomy, particularly in coun-
tries with a low prevalence of TB [V-B].
& Disseminated TB should be suspected in the presence of
clinical manifestations that vary depending on the pre-
dominantly involved site and are associated with initially
aspecific systemic signs and symptoms [V-B]. The only
pathognomonic sign is the ophthalmoscopic presence of
choroidal tubercles in about one-third of cases [V-A].
& The use of a TSTand/or IGRA is recommended in order to
diagnose TB in children aged ≥5 years [III-A]. The choice
of one or the other method should be based on individual
considerations, including an evaluation of the likelihood
that the child will or will not return to the centre for the
interpretation of TST results, whether or not he or she has
received BCG vaccination (a confirmatory IGRA is any
case recommended if the TST result is <15 mm), and the
availability of a TST and/or IGRA at the centre [III-A].
& The use of an IGRA alone is not recommended for diag-
nosing TB in children aged <5 years; a TST is the only test
that should be used [V-C]. However, the combined use of
a TSTand IGRA is possible in selected cases, especially if
the child has previously received BCG vaccination [V-C],
although it must be remembered that there are still doubts
as to how to interpret discordant results [V-C].
& Regardless of age, a negative or indeterminate IGRA re-
sult should never be considered as excluding a diagnosis
of tubercular infection [III-A].
& The performance of TSTs and IGRAs is suboptimal in the
case of children with T lymphocyte immunodepression
[III-A]. The risk of tuberculous infection or disease in such
patients can be evaluated by combining the results of both
tests with the findings of clinical, radiological and microbi-
ological investigations [V-B]. Nevertheless, the interpreta-
tion of conflicting test results remains doubtful, and so
immunodepressed children should prudently be considered
infected even if only one of the tests is positive [V-B].
& The use of serial IGRAs is not recommended because it is
not helpful in monitoring the response to anti-TB therapy,
and does not predict the risk of latent infection evolving
into TB disease in children [III-A].
& A microbiological diagnosis must be based on samples
originating from the involved site and preferably collected
before the start of anti-TB treatment [III-A]. In order to
increase sensitivity, it is recommended to test for pulmo-
nary TB using gastric aspirate or induced sputum samples
collected on three consecutive days [III-A]. A single sam-
ple can be used only in the case of broncho-lavage [III-A].
Induced sputum samples should always be indicated as
such because their salivary appearancemay otherwise lead
to them being considered Bunsuitable^ by the laboratory
[III-A].
& Minimummicrobiological diagnostics must include micros-
copy and cultures [III-A]. A microscopic examination is
only moderately sensitive in the case of pediatric TB; a gene
amplification test is more likely to be diagnostic [IV-B].
Negative microscopic results do not exclude a diagnosis of
TB even if obtained onmultiple samples [III-A]. In addition
to microscopy and culture tests, a gene amplification test
should be requested until a diagnosis has been established
[IV-B]. If the laboratory is so equipped, it may be useful to
reserve one of the available clinical samples for testing on
the GeneXpert platform [V-B]. If MDRTB is suspected in a
patient with a microbiological diagnosis of TB, it is advis-
able to carry out a genotypic resistance assay (e.g.
GeneXpert or LPA) before starting treatment [IV-B].
& Chest radiography remains the most suitable imaging
technique for evaluating pediatric pulmonary TB [IV-A].
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The presence of asymmetric/unilateral mediastinic and hi-
lar lymphadenomegalies should prompt a suspicion of
TB, especially in children aged <5 years [V-B].
Cavitations are also suggestive [V-B]. The lateral projec-
tion may be useful in doubtful cases [IV-B].
& After traditional radiology, the investigation can be com-
pleted using CT with contrast medium, which is particu-
larly useful in children aged <5 years (especially those
aged <2 years) in whom conventional chest radiography
is often insufficient because of the physiological protru-
sion of the thymus [IV-B].
& TheMarais anatomo-radiological classification can distin-
guish parenchymal and lymph node disease and their re-
spective evolutions [V-B].
& All patients with extra-pulmonary TB should undergo
chest radiography [IV-A], which can be integrated with
CT in the cases described above [IV-B].
& Ultrasonography is the investigation of first choice in the
case of peripheral tuberculous lymphadenitis [IV-B].
& If osteo-articular TB is suspected, the first diagnostic and
follow-up approach is conventional radiology [IV-A].
MRI with contrast medium generally allows a better eval-
uation of the extent of bone and joint involvement, al-
though it does not usually increase diagnostic specificity
[V-B]. MRI with contrast medium is fundamental for the
volumetric evaluation of ankylosis and the assessment of
osteopenia in patients with spondylitis/spondylodiscitis,
as well as in order to obtain a complete spinal picture
during follow-up [IV-B].
& MRI provides much more information about CNS TB
than CT, the use of which is currently limited to emergen-
cy situations or the monitoring of hydroencephalus sec-
ondary to tuberculous meningo-encephalitis [IV-A].
& Imaging is also often used to diagnose abdominal TB;
standard radiography can reveal signs of occlusion but
ultrasonography and/or CT are the recommended imaging
techniques [IV-B].
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